• Honam Mathematical Journal
• /
• 제36권3호
• /
• pp.623-635
• /
• 2014

Classications of (${\alpha},{\beta}$)-fuzzy subalgebras of BCK/BCI-algebras are discussed. Relations between (${\in},{\in}{\vee}q$)-fuzzy subalgebras and ($q,{\in}{\vee}q$)-fuzzy subalgebras are established. Given special sets, so called t-q-set and t-${\in}{\vee}q$-set, conditions for the t-q-set and t-${\in}{\vee}q$-set to be subalgebras are considered. The notions of $({\in},q)^{max}$-fuzzy subalgebra, $(q,{\in})^{max}$-fuzzy subalgebra and $(q,{\in}{\vee}q)^{max}$-fuzzy subalgebra are introduced. Conditions for a fuzzy set to be an $({\in},q)^{max}$-fuzzy subalgebra, a $(q,{\in})^{max}$-fuzzy subalgebra and a $(q,{\in}{\vee}q)^{max}$-fuzzy subalgebra are considered.

• Journal of the Institute of Electronics Engineers of Korea SD
• /
• 제37권3호
• /
• pp.20-26
• /
• 2000

In this work, the degradation of g$_{m}$ , f$_{T}$ and f$_{max}$ of RF-CMOS devices have been characterized at elevated temperature. Since MOS transistors in RF applications are usually in saturation region, a simple empirical model for temperature dependence of g$_{m}$ at any measurement bias has been suggested. Because f$_{T}$ and f$_{max}$ of CMOS devices are proportional to g$_{m}$, the temperature dependence of f$_{T}$ and f$_{max}$ could be obtained from the temperature dependence of g$_{m}$. It was found that the degradation of f$_{T}$ and f$_{max}$ at elevated temperature was due to the degradation of g$_{m}$. From the correlation between DC and RF performances of CMOS devices, we can predict the enhanced f$_{T}$ and f$_{max}$ performances at low temperature.

• Journal of Pharmaceutical Investigation
• /
• 제32권1호
• /
• pp.47-54
• /
• 2002

Cimetropium bromide, a quaternary ammonium compound which is chemically related to scopolamine, exhibits its antispasmodic activity by competing with acetylcholine for the muscarinic receptors of the smooth muscle of gastrointestinal tract. The drug has been used for the treatment of various disorders involving spasms of the musculature of the gastrointestinal, biliary and genitourinary tracts. The purpose of the present study was to evaluate the bioequivalence of two cimetropium bromide tablets, $Algiron^{TM}$ (Boehringer Ingelheim Korea Ltd.) and $Alpit^{TM}$ (Hana Pharmaceutical Co., Ltd.), according to the prior and revised guidelines of Korea Food and Drug Administration (KFDA). The cimetropium bromide release from the two cimetropium bromide tablets in vitro was tested using KP VII Apparatus II method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty normal male volunteers, $25.25{\pm}2.10$ years in age and $65.76{\pm}6.39$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After three tablets containing 50 mg of cimetropium bromide per tablet were orally administered, blood was taken at predetermined time intervals and the concentrations of cimetropium bromide in serum were determined using HPLC method with UV detector. The dissolution profiles of two cimetropium bromide tablets were very similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AUC_t,\;C_{max}\;and\;T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using non-transformed and logarithmically transformed $AUC_t\;and\;C_{max}$. The results showed that the differences in $AUC_t,\;C_{max}\;and\;T_{max}$ between two tablets based on the $Algiron^{TM}$ were 2.19%, -5.97% and 3.49%, respectively. Minimum detectable differences $({\Delta})\;at \;{\alpha}=0.05\;and\;1-{\beta}=0.8$ were less than 20% (e.g., 13.71 %, 19.05% and 15.11% for $AUC_t,\;C_{max}\;and\;T_{max}$, respectively). The powers $(1-{\beta})\;at\;{\alpha}=0.05,\;{\Delta}=0.2\;for\;AUC_t$, $C_{max}\;and\;T_{max}$ were 97.79%, 83.22% and 95.60%, respectively. The 90% confidence intervals were within ${\pm}20%$ (e.g., $-5.84{\sim}10.21,\;-17.11{\sim}5.18\;and\;-5.35{\sim}12.33\;for\;AUC_t,\;C_{max}\;and\;T_{max}$, respectively). There were no sequence effect between two tablets in logarithmically transformed $AUC_t\;and\;C_{max}$. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., $0.94{\sim}1.10\;and\;0.85{\sim}1.05\;for\;AUC_t\;and\;C_{max}$, respectively). Two parameters met the criteria of prior and revised KFDA guideline for bioequivalence, indicating that $Alpit^{TM}$ tablet is bioequivalent to $Algiron^{TM}$ tablet.

• The Journal of the Korea institute of electronic communication sciences
• /
• 제9권7호
• /
• pp.827-834
• /
• 2014

In this paper, a triple-band U-shaped monopole antenna with T-shaped stub for WLAN(Wireless Local Area Networks)/WiMAX(World interoperability for Microwave Access) applications. The proposed antenna is based on a planar monopole design, and composed of U-shaped of radiating patch, T-shaped strip in U-shaped, for triple-band operation. To obtain the optimized parameters, we used the simulator, Ansoft's High Frequency Structure Simulator(HFSS) and found the parameters that greatly effect antenna characteristics. Using the obtained parameters, the antenna is fabricated. The numerical and experiment results demonstrated that the proposed antenna satisfied the -10 dB impedance bandwidth requirement while simultaneously covering the WLAN and WiMAX bands. And characteristics of gain and radiation patterns are determined for WLAN/WiMAX application.

• Journal of the Korean Society of Food Science and Nutrition
• /
• 제24권3호
• /
• pp.384-388
• /
• 1995

High content of polyunsaturated fatty acid in fish oil makes it very susceptible to oxidation, which prevent fish oil from successful application to food processing or functional foods. To resolve this problem, oxidation stability model of fish oil was developed using the following differential equation : $dp/dt=k{\cdot}p(t){\cdot}[P_{max}\;-\;p(t)]$. This differential equation can be intergrated using analytical techniques to give : $p(t)=P_{max}/[1\;+\;[(P_{max}/P_{(0)})\;-\;-1]{\cdot}EXP(-K_p{\cdot}t)]$. At 50, 60, 70 and $80^{\circ}C,\;K_p$ were 0.00535, 0.01345, 0.02516 and 0.04675, respectively. The proposed model was well agreed with the measured data except for some minor deviations. In addition, $K_p$ was expressed as a function of temperature : $K_p=(1/P_{max})EXP\;[1\;-\;(8148/T)+20.1]$. Where T is absolute temperature($^{o}K$).

• Biomolecules & Therapeutics
• /
• 제15권2호
• /
• pp.118-122
• /
• 2007

This study was performed to evaluate the bioequivalency between the Osmetone$^{TM}$ Tablet (Myeongmoon Pharm. Co., Ltd.) as a test formulation and the Relafen$^{TM}$ Tablet (Handok Pharm. Co., Ltd.) as a reference formulation. Twenty-four healthy male volunteers were administered the formulations by the randomized Latin square crossover design, and the plasma samples were determined by a high performance liquid chromatography (HPLC) with Ultra-Violet (UV) detector. AUC$_t$, C$_{max}$ and T$_{max}$ were obtained from the time-plasma concentration curves, and log-transformed AUC$_t$ and C$_{max}$ and log-untransformed T$_{max}$ values for two formulations were compared by statistical tests and analysis of variation. AUC$_t$ was determined to be 897.8${\pm}$431.1 ug.hr/ml for the reference formulation and 902.3${\pm}$408.4 ug.hr/ml for the test formulation. The mean values of C$_{max}$ for the reference and test formulations were 24.2${\pm}$8.9 and 24.0${\pm}$9.5 ug/ml, respectively. The AUC$_t$ and C$_{max}$ ratios of the reference Relafen$^{TM}$ Tablet to the test Osmetone$^{TM}$ Tablet were +5.01% and -0.83%, respectively, showing that the mean differences were satisfied the acceptance criteria within 20%. The results from analysis of variance for logtransformed AUC$_t$ and C$_{max}$ indicated that sequence effects between groups were not exerted and 90% confidence limits of the mean differences for AUC$_t$ and C$_{max}$ were located in ranges from log 0.80 to log 1.25, satisfying the acceptance criteria of the KFDA bioequivalence. The Osmetone$^{TM}$ Tablet as the test formulation was considered to be bioequivalant to the Relafen$^{TM}$ Tablet used as its reference formulation, based on AUC$_t$ and C$_{max}$ values.

• Biomolecules & Therapeutics
• /
• 제14권1호
• /
• pp.50-55
• /
• 2006

The objective of the study was to evaluate the bioequivalency between the $Rozid^{TM}$ Tablet (Ilhwa Pharm. Co., Ltd.) as a test formulation and the $Rulid^{TM}$ Tablet (Handok Pharm. Co., Ltd) as a reference formulation. Twenty-four healthy male volunteers were administered the formulations by the randomized Latin square crossover design, and the plasma samples were determined by a high performance liquid chromatography (HPLC) with fluorescence detector. $AUC_t,\;C_{max}\;and\;T_{max}$ were obtained from the time-plasma concentration curves, and log-transformed $AUC_t\;and\;C_{max}$ and log-untransformed $T_{max}$ values for two formulations were compared by statistical tests and analysis of variation. $AUC_t$ was determined to be $63.30{\pm}25.57{\mu}g.hr/ml$ for the test formulation and $64.02{\pm}29.27mg.hr/ml$ for the reference formulation. The mean values of $C_{max}$ for the test and reference formulations were $5.07{\pm}2.14\;and\;5.53{\pm}2.60{\mu}g/ml$, respectively. The $AUC_t,\;and\;C_{max}$ ratios of the test $Rozid^{TM}$ Tablet to the reference $Rulid^{TM}$ Tablet were -1.12% and -8.32%, respectively, showing that the mean differences were satisfied the acceptance criteria within 20%. The results from analysis of variance for log-transformed $AUC_t,\;and\;C_{max}$ indicated that sequence effects between groups were not exerted and 90% confidence limits of the mean differences for $AUC_t,\;and\;C_{max}$ were located in ranges from log 0.80 and log 1.25, satisfying the acceptance criteria of the KFDA bioequivalence. The RozidTM Tablet as the test formulation was considered to be bioequivalent to the RulidTM Tablet used as its reference formulation, based on $AUC_t,\;and\;C_{max}$ values.

• Biomolecules & Therapeutics
• /
• 제11권1호
• /
• pp.58-64
• /
• 2003

Ondansetron is a potent, highly selective 5-hydroxytryptamin $e_3$(5-H $T_3$) receptor-antagonist, for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiography, and the treatment of post-operative nausea and vomiting. The purpose of the present study was to evaluate the bioequivalence of two ondansetron tablets, Zofran (Glaxo Smithcline Korea Ltd.) and Onfran (Korea United Pharmaceutical Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). Eighteen normal male volunteers, 24.39$\pm$1.69 year in age and 69.00$\pm$6.74kg in body weight, were divided into two groups and a randomized 2${\times}$2 cross-over study was employed. After one tablet containing 8mg of ondansetron was orally administered, blood was taken at predetermined time intervals and the concentrations of ondansetron in plasma were determined using HPLC with UV detector. Pharmacokinetic parameters such as AVC, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters. The results showed that the differences in AUC, $C_{max}$ and T max between two tablets were 5.83％, 5.75％ and －5.71％, respectively when calculated against the Zofran, tablet. The powers (1-$\beta$) for AUC, $C_{max}$ and $T_{max}$ were above 90％, above 90％ and below 60％, respectively. Minimum detectable differences($\Delta$) at alpha=0.1 and 1-$\beta$=0.8 were less than 20％ (e.g., 12.74％ and 11.78％ for AUC and $C_{max}$ respectively). But minimum detectable differences($\Delta$) at alpha=0.1 and 1-$\beta$=0.8 for $T_{max}$ were more than 20％ (e.g., 34.22％). The 90％ confidence intervals were within $\pm$20％ (e.g., -2.73∼14.39 and -2.16∼13.67 for AUC and $C_{max}$ respectively). But 90％ confidence intervals for $T_{max}$ were not within $\pm$20％ (e.g., -28.71∼17.28). Another ANOVA test was conducted for logarithmically transformed AUC and $C_{max}$. These results showed that there are no significant difference in AUC and $C_{max}$ between the two formulations: The differences between the formulations in these log transformed parameters were all for less than 20％ (e.g., 5.83％ and 5.75％ for AUC and $C_{max}$ respectively). The 90％ confidence intervals for the log transformed data were the acceptance range of log 0.8 to log 1.25 (e.g., log 0.99∼log 1.15 and log 0.98∼log 1.15 for AUC and $C_{max}$ respectively). The major parameters, AUC and $C_{max}$, met the criteria of KFDA for bioequivalence although $T_{max}$ did not meet the criteria of KFDA for bioequivalence, indicating that Onfran tablet is bioequivalent to Zofrm1 tablet.t is bioequivalent to Zofrm1 tablet.m1 tablet.m1 tablet.m1 tablet.

• Journal of Korean Ophthalmic Optics Society
• /
• 제6권2호
• /
• pp.59-63
• /
• 2001

Using the rotation of two polarizer plate and the area of transmittance In the visual light region measured by spectrophotometer, we obtained the luminance to measure the Contrast Sensitivity, and calculated the values of $L_{min}$ and ${\theta}_{min}$ after fixed the average contrast, $L_{max}$ and ${\theta}_{max}$ values from the values of two contrasts. Then, when it was fixed by $L_{max}=4000(T%nm)$ and ${\theta}_{max}=44.1^{\circ}$, $L_{min}$ and ${\theta}_{min}$ values were respectively given by 1333, 2666, 3920(T%nm) and 56.6, 54.3, $45^{\circ}$ in Cs values of 2.5, 100.

• The Journal of the Institute of Internet, Broadcasting and Communication
• /
• 제14권2호
• /
• pp.59-64
• /
• 2014

This paper address the scheme for WiMAX backhaul in mobile communication network. These days most ISPs has implemented Wi-Fi backhaul using T1/E1 and DSL. if WiMAX is installed as the alternative to the mobile backhaul, it can decrease the costs drastically for the installation and operations. And it will be one of the best cost-effective solutions to cover the service areas which has not the wired communication infrastructure. WiMAX can be used for Base station, Subscriber Station, and Relay. In this paper, the performance is measured for downstream and upstream using NAT and port forwarding functions by configuring WiMAX server and WiMAX SS.